ESO Guideline on Covert Cerebral Small Vessel Disease

Joanna M Wardlaw, Stephanie Debette, Hanna Jokinen, Frank-Erik De Leeuw, Leonardo Pantoni, Hugues Chabriat, Julie Staals, Fergus Doubal, Salvatore Rudilosso, Sebastian Eppinger, Sabrina Schilling, Raffaele Ornello, Christian Enzinger, Charlotte Cordonnier, Martin Taylor-Rowan, Arne G. Lindgren

Research output: Contribution to journalArticleScientificpeer-review

Abstract

'Covert' cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about management of ccSVD, specifically white matter hyperintensities and lacunes, to prevent adverse clinical outcomes. The guidelines were developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We prioritised the clinical outcomes of stroke, cognitive decline or dementia, dependency, death, mobility and mood disorders, and interventions of blood pressure lowering, antiplatelet drugs, lipid lowering, lifestyle modifications, glucose lowering and conventional treatments for dementia. We systematically reviewed the literature, assessed the evidence, formulated evidence-based recommendations where feasible, and expert consensus statements. We found little direct evidence, mostly of low quality. We recommend patients with ccSVD and hypertension to have their blood pressure well controlled; lower blood pressure targets may reduce ccSVD progression. We do not recommend antiplatelet drugs such as aspirin in ccSVD. We found little evidence on lipid lowering in ccSVD. Smoking cessation is a health priority. We recommend regular exercise which may benefit cognition, and a healthy diet, good sleep habits, avoiding obesity and stress for general health reasons. In ccSVD, we found no evidence for glucose control in the absence of diabetes or for conventional Alzheimer dementia treatments. Randomised controlled trials with clinical endpoints are a priority for ccSVD.

Original languageEnglish
Article number23969873211012132
JournalEuropean Stroke Journal
Volume6
Issue number2
Pages (from-to)CXI-CLXII
Number of pages52
ISSN2396-9873
DOIs
Publication statusPublished - Jun 2021
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3124 Neurology and psychiatry
  • 515 Psychology
  • White matter hyperintensities
  • lacunes
  • cerebral small vessel disease
  • leukoaraiosis
  • silent brain infarcts
  • covert
  • prevention
  • stroke
  • dementia
  • recommendations
  • outcome
  • VASCULAR COGNITIVE IMPAIRMENT
  • WHITE-MATTER HYPERINTENSITIES
  • HEALTH-CARE PROFESSIONALS
  • MIDLIFE BLOOD-PRESSURE
  • SILENT BRAIN INFARCTS
  • RECENT LACUNAR STROKE
  • DOUBLE-BLIND
  • PRIMARY PREVENTION
  • PHYSICAL-ACTIVITY
  • CEREBROVASCULAR-DISEASE

Cite this